What We’re Reading: US Adults Had Low Trust in Public Info During Pandemic; Higher Risk of Cancer Death; Unproven Birth Drug to Be Removed From US Market

US Adults Had Low Trust in Public Health Info During COVID-19 Pandemic, Said Survey

More than 33% of United States adults said they trusted the CDC to give quality health information during the COVID-19 pandemic, while 25% trusted state and local health departments, and 10% said they had no trust in any of these sources, according to the first nationally representative survey on the public’s attitudes on health information sources, reported the Center for Infectious Disease Research and Policy. Harvard University researchers led a team who conducted the survey of 4208 adults from February 1 to 22, 2022, about why they trusted federal, state, and local public health agencies during the pandemic.

Incarcerated People More Likely to Die From Cancer

A recent study suggests that people who have been incarcerated are more likely to die when they have cancer than those who were never incarcerated, a by-product of systems that weren’t designed to care for people in the criminal justice system or after their release, said PBS. The study examined 10 years of data from over 216,000 adults in Connecticut diagnosed with invasive cancers, and compared with people who were never incarcerated, researchers found a “significantly higher” risk of dying from cancer for those who had been diagnosed in jail or prison or shortly after they were released.

Unproven Birth Drug Manufacturer to Remove Drug From US Market

Covis, the manufacturer of preterm birth prevention drug hydroxyprogesterone caporate injection (Makena), will voluntarily revoke the product from the United States market after the FDA indicated it would recall the drug through its regulatory authority, reported The Associated Press. Results of a confirmatory trial in 2018 showed the drug did not help pregnant mothers reach full term. The FDA had been trying to remove the drug from the market since then, even as the company appealed to try to do additional research.